Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IOVA)

Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program

GlobeNewswire October 11, 2018

Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2018

Iovance Biotherapeutics to Present at Two Investor Conferences in September

GlobeNewswire August 29, 2018

Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center

GlobeNewswire August 16, 2018

Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2018

Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

GlobeNewswire July 30, 2018

Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma

GlobeNewswire June 7, 2018

Iovance Biotherapeutics to Present at Two Investor Conferences in June

GlobeNewswire May 31, 2018

Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2018

Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018

GlobeNewswire May 3, 2018

Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May

GlobeNewswire May 2, 2018

Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018

GlobeNewswire April 4, 2018

Iovance Biotherapeutics Inc to Host Earnings Call

Accesswire March 12, 2018

Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018

GlobeNewswire March 8, 2018

Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March

GlobeNewswire March 7, 2018

Johnson Fistel, LLP Announces Investigations of RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc.; Investors Encouraged to Contact Firm

PR Newswire March 6, 2018

IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA

PR Newswire March 2, 2018

Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

GlobeNewswire March 1, 2018

IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. – IOVA

Business Wire February 23, 2018

Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering

GlobeNewswire January 29, 2018